Suppr超能文献

再次行主动脉弓手术的当代系列研究。

Re-Operative Aortic Arch Surgery in a Contemporary Series.

机构信息

Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.

Dell Children's Medical Center, The University of Texas at Austin.

出版信息

Semin Thorac Cardiovasc Surg. 2022 Summer;34(2):377-382. doi: 10.1053/j.semtcvs.2021.03.035. Epub 2021 May 8.

Abstract

Re-operative aortic arch operations (REDO) following previous cardiac surgery are challenging procedures associated with significant morbidity and mortality. We investigated post-operative outcomes for patients undergoing REDO and identified risk-factors for mortality in a contemporary series. From 1/2005-6/2018, 365 consecutive patients at an academic center underwent REDO: 257 HEMIARCH and 108 COMPLETE arch (45 stage I elephant trunk, 63 total arch) replacements. Outcomes included mortality and major adverse events. Long-term survival was determined with Kaplan-Meier analysis, and risk-factors for mortality were assessed with Cox proportional hazards regression. Operative mortality for the entire cohort was 6.8%, and rates of stroke, cardiac arrest, and renal failure were 6.0%, 7.4%, and 10.4%. Compared to HEMIARCH, COMPLETE patients had an increased incidence of renal failure requiring dialysis (15.7% vs 8.2%, p = 0.031) and re-exploration for bleeding or delayed chest closure (19.4% vs. 11.7%, p = 0.051). Although operative mortality was similar in both cohorts, long-term follow-up mortality (38.0% vs 26.8%, p = 0.047) was higher among COMPLETE vs. HEMIARCH. Predictors of overall mortality among all-comers undergoing REDO included older age, low body surface area, endocarditis, ejection fraction <30%, emergent status of operation, extended cardiopulmonary bypass duration, intra-aortic balloon pump use, and a more extensive arch operation. Previous aortic surgery was not a risk-factor for mortality. Among all-comers undergoing REDO, survival was 81.4% at 1 year, 66.7% at 5 years, and 56.4% at 10 years of follow-up. While early postoperative outcomes are similar among HEMIARCH and COMPLETE, a more extensive arch-replacement is an independent risk-factor for overall mortality in REDO. Using appropriate clinical indications in the current era, REDO remains a viable option for selected patients.

摘要

在先前的心脏手术后进行再次主动脉弓手术(redo)是一项具有挑战性的手术,其与较高的发病率和死亡率相关。我们研究了 redo 患者的术后结果,并在一个现代系列中确定了死亡率的危险因素。从 2005 年 1 月至 2018 年 6 月,一家学术中心的 365 名连续患者接受了 redo:257 例 hemiarch 和 108 例全弓(45 例一期象鼻手术,63 例全弓)置换。结果包括死亡率和主要不良事件。通过 Kaplan-Meier 分析确定长期生存率,并使用 Cox 比例风险回归评估死亡率的危险因素。整个队列的手术死亡率为 6.8%,卒中、心脏骤停和肾衰竭的发生率分别为 6.0%、7.4%和 10.4%。与 hemiarch 相比,全弓患者的肾衰竭需要透析的发生率更高(15.7%比 8.2%,p=0.031),以及因出血或延迟胸部闭合而再次探查的发生率更高(19.4%比 11.7%,p=0.051)。尽管两个队列的手术死亡率相似,但全弓组的长期随访死亡率(38.0%比 26.8%,p=0.047)高于 hemiarch 组。所有接受 redo 的患者的总体死亡率预测因素包括年龄较大、低体表面积、心内膜炎、射血分数<30%、手术紧急状态、体外循环时间延长、主动脉内球囊泵使用以及更广泛的弓部手术。先前的主动脉手术不是死亡率的危险因素。在所有接受 redo 的患者中,1 年时的生存率为 81.4%,5 年时为 66.7%,10 年时为 56.4%。尽管 hemiarch 和全弓的术后早期结果相似,但更广泛的弓部置换是 redo 患者总体死亡率的独立危险因素。在当前时代,使用适当的临床适应证,redo 仍然是选择患者的可行选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验